In AGE-exposed HUVECs, HBX 41108 pretreatment partly restored the CCK-8 signal and reduced G0/G1 accumulation, senescence staining and p53/p21 protein abundance. These are model-specific pharmacological observations; parallel USP7 knockdown does not establish compound selectivity. [2]
Broad DUB inhibition in a 32-enzyme panel
Biochemical assay · 32 recombinant human DUBs with their preferred diubiquitin substrates [1]
HBX 41,108 inhibited a broad panel of DUBs rather than showing USP7-specific inhibition.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 and 5 μM
- Exposure duration
- 35 min preincubation, then 60 min substrate incubation at 30°C
- Method
- Cell-free inhibitor panel; enzyme-specific diubiquitin substrates.
- Reported limits
- Vehicle identity and concentration not specified in the retrieved main text; SI acquired but not read.
Methods and source locations
Compound reported in the paper: HBX 41108; Compound label in the paper: HBX 41,108
Applies to the named research compound under the reported conditions; no tested Adooq lot, salt conversion, or human efficacy inference.
Figure 3 and caption; Methods: Materials; In vitro DUB assays and inhibitor screening
DUBs inhibited by more than 70% at 5 μM: MALDI-TOF quantitation of monoubiquitin released from diubiquitin; duplicate independent experiments. — Results: Assessing potency and selectivity of DUB inhibitors; Figure 3 and caption
USP7 and USP8 concentration-response comparison
Biochemical assay · Recombinant full-length human USP7 (His-tagged) with K11-linked diubiquitin; full-length human USP8 (His-tagged) with K63-linked diubiquitin [1]
In this assay, HBX 41,108 inhibited USP8 more potently than USP7. This limits attribution of cellular effects to USP7 alone.
Literature-Reported Treatment Conditions
- Exposure duration
- 35 min preincubation, then 60 min substrate incubation at 30°C
- Method
- Cell-free concentration-response assays; no-inhibitor conditions included.
- Reported limits
- Exact per-enzyme concentration series and compound vehicle are not transcribed from SI; no concentrations inferred from curves.
Methods and source locations
Compound reported in the paper: HBX 41108; Compound label in the paper: HBX 41,108
Applies to the named research compound under the reported conditions; no tested Adooq lot, salt conversion, or human efficacy inference.
Figure 4 and caption; Table 1 (construct descriptors only); Methods: In vitro DUB assays and inhibitor screening
USP7-mediated K11-linked diubiquitin hydrolysis: MALDI-TOF; four-parameter logistic fitting. Figure 4 reports three different experiments and SD error bars; the meaning of ± on fitted IC50 annotations is not separately defined. — Figure 4, HBX 41,108 column, middle panel; caption; Results: Assessing potency and selectivity
USP8-mediated K63-linked diubiquitin hydrolysis: Same assay family and fitting approach; substrate differs from USP7. Figure 4 reports three different experiments and SD error bars; fitted-IC50 ± semantics are not separately defined. — Figure 4, HBX 41,108 column, top panel and caption
Endothelial-cell responses to HBX 41108 under AGE exposure
Cell-based study · Human umbilical vein endothelial cells (HUVECs), exposed to advanced glycation end products (AGEs) [2]
HBX 41108 partly reversed AGE-associated loss of CCK-8 signal, G0/G1 accumulation and senescence staining, and lowered p53/p21 protein signals relative to AGE-exposed vehicle-labelled controls. A parallel USP7-knockdown arm supported pathway involvement but does not establish drug selectivity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM HBX 41108; subsequent AGEs 250 μg/mL
- Exposure duration
- HBX 41108 for 24 h before AGEs for 24 h; CCK-8 readouts at 0, 12, 24 and 48 h after plating treated cells
- Method
- Pharmacological pretreatment followed by AGE exposure; parallel genetic comparator was a separate arm, not a drug combination.
- Reported limits
- Vehicle composition and whether HBX remained present throughout AGE exposure are not specified. Replicate type beyond global triplicate statement is not defined.
Methods and source locations
Compound reported in the paper: HBX 41108; Compound label in the paper: HBX 41108
Applies to the named research compound under the reported conditions; no tested Adooq lot, salt conversion, or human efficacy inference.
Figure 2C–H; Methods: Experimental grouping; CCK-8 assay; Flow cytometry of cell cycle; Senescence β-galactosidase staining; Western blot analysis; Statistical analysis
CCK-8 signal, cell-cycle distribution and senescence-associated β-galactosidase staining: CCK-8, flow cytometry and SA-β-Gal staining; global statistics: experiments in triplicate, mean±SD. Exact effect sizes not extracted from graphs. — Figure 2C–F and caption; Results: Inhibiting USP7 expression and its deubiquitinating activity
p53 and p21 protein abundance: Immunoblotting with GAPDH loading control and quantification; no exact bar heights inferred. — Figure 2G,H and caption